Extending the Time Window for Endovascular and Pharmacological Reperfusion - PubMed (original) (raw)
Review
Extending the Time Window for Endovascular and Pharmacological Reperfusion
Nils Henninger et al. Transl Stroke Res. 2016 Aug.
Abstract
Pharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7-15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.
Keywords: Animal modeling; Endovascular; Imaging; Ischemic stroke; Neuroprotection; Recanalization; Reperfusion injury; Thrombolysis; Time window; Tissue-type plasminogen activator.
Similar articles
- Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke.
Kufner A, Nolte CH, Galinovic I, Brunecker P, Kufner GM, Endres M, Fiebach JB, Ebinger M. Kufner A, et al. Stroke. 2013 Feb;44(2):407-13. doi: 10.1161/STROKEAHA.112.662148. Epub 2013 Jan 3. Stroke. 2013. PMID: 23287785 Clinical Trial. - Acute Ischemic Stroke Therapy Overview.
Catanese L, Tarsia J, Fisher M. Catanese L, et al. Circ Res. 2017 Feb 3;120(3):541-558. doi: 10.1161/CIRCRESAHA.116.309278. Circ Res. 2017. PMID: 28154103 Review. - Bridging-therapy with intravenous recombinant tissue plasminogen activator improves functional outcome in patients with endovascular treatment in acute stroke.
Maier IL, Behme D, Schnieder M, Tsogkas I, Schregel K, Kleinknecht A, Wasser K, Bähr M, Knauth M, Psychogios M, Liman J. Maier IL, et al. J Neurol Sci. 2017 Jan 15;372:300-304. doi: 10.1016/j.jns.2016.12.001. Epub 2016 Dec 5. J Neurol Sci. 2017. PMID: 28017233 - Thrombolysis and reperfusion: advanced understanding of early management strategies in acute ischemic stroke.
Zhang D, Zou X, Sy C, Qin H, Wang Y, Liao X, Liu L. Zhang D, et al. Neurol Res. 2014 May;36(5):391-6. doi: 10.1179/1743132814Y.0000000349. Epub 2014 Mar 25. Neurol Res. 2014. PMID: 24661072 Review. - [Intravenous thrombolysis for acute ischemic stroke: past, present and future].
Hayakawa M. Hayakawa M. Rinsho Shinkeigaku. 2014;54(12):1197-9. doi: 10.5692/clinicalneurol.54.1197. Rinsho Shinkeigaku. 2014. PMID: 25672743 Review. Japanese.
Cited by
- Mechanisms, Imaging, and Therapy in Stroke Recovery.
Xing C, Hayakawa K, Lo EH. Xing C, et al. Transl Stroke Res. 2017 Feb;8(1):1-2. doi: 10.1007/s12975-016-0503-5. Epub 2016 Oct 7. Transl Stroke Res. 2017. PMID: 27714670 Free PMC article. No abstract available. - Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion: Study Protocol for a Prospective, Open Label, Single-Center Study With 12 Months of Follow-Up.
Staszewski J, Stȩpień A, Piusińska-Macoch R, Dȩbiec A, Gniadek-Olejniczak K, Frankowska E, Maliborski A, Chadaide Z, Balo D, Król B, Namias R, Harston G, Mróz J, Piasecki P. Staszewski J, et al. Front Neurol. 2022 Jul 4;13:910697. doi: 10.3389/fneur.2022.910697. eCollection 2022. Front Neurol. 2022. PMID: 35860483 Free PMC article. - Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones.
Lapchak PA, Lara JM, Boitano PD. Lapchak PA, et al. Transl Stroke Res. 2017 Apr 12. doi: 10.1007/s12975-017-0533-7. Online ahead of print. Transl Stroke Res. 2017. PMID: 28405804 - Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents.
Chua P, Lim WK. Chua P, et al. Sci Rep. 2021 Apr 14;11(1):8096. doi: 10.1038/s41598-021-87431-4. Sci Rep. 2021. PMID: 33854099 Free PMC article. - Ligustilide Attenuates Ischemia Reperfusion-Induced Hippocampal Neuronal Apoptosis via Activating the PI3K/Akt Pathway.
Wu Q, Mao Z, Liu J, Huang J, Wang N. Wu Q, et al. Front Pharmacol. 2020 Jun 26;11:979. doi: 10.3389/fphar.2020.00979. eCollection 2020. Front Pharmacol. 2020. PMID: 32676033 Free PMC article.
References
- J Cereb Blood Flow Metab. 2009 Jan;29(1):119-29 - PubMed
- Stroke. 2006 May;37(5):1283-7 - PubMed
- Stroke. 2015 Dec;46(12):3507-13 - PubMed
- Brain. 2007 Dec;130(Pt 12):3063-74 - PubMed
- J Neurointerv Surg. 2014 Mar;6(2):91-5 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical